Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?

被引:4
|
作者
Boerner, Thomas [1 ]
Zambirinis, Constantinos [1 ]
Gagniere, Johan [1 ,4 ,5 ]
Chou, Joanne F. [2 ]
Gonen, Mithat [2 ]
Kemeny, Nancy E. [3 ]
Cercek, Andrea [3 ]
Connell, Louise C. [3 ]
Kingham, Thomas P. [1 ]
Allen, Peter J. [1 ,6 ]
Balachandran, Vinod P. [1 ]
Drebin, Jeffrey [1 ]
Jarnagin, William R. [1 ]
D'Angelica, Michael, I [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[4] Clermont Auvergne Univ, Univ Hosp Clermont Ferrand, Dept Digest & Hepatobiliary Surg, Clermont Ferrand, France
[5] Clermont Auvergne Univ, U1071 Inserm, Clermont Ferrand, France
[6] Duke Univ, Dept Surg, Durham, NC USA
基金
美国国家卫生研究院;
关键词
HEPATIC ARTERIAL INFUSION; RANDOMIZED PHASE-III; COLON-CANCER; POOLED ANALYSIS; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; RESECTION; SURVIVAL; COMBINATION;
D O I
10.1016/j.hpb.2020.08.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. Methods: A retrospective analysis of patients with early CLM ( 12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan?Meier methods and Cox proportional hazards models. Results: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44?0.94, p = 0.022) and allcause mortality (HRadj: 0.54, 95%CI:0.36?0.81, p = 0.003) compared to Surgery alone patients. Largest tumor 5 cm (HRadj: 2.03, 95%CI: 1.41?2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29?2.89, p = 0.002) were independently associated with worse OS. Background: The utility of adjuvant chemotherapy after resection of colorectal liver metastasis (CLM) in patients with rapid recurrence after adjuvant chemotherapy for their primary tumor is unclear. The aim of this study was to evaluate the oncologic benefit of adjuvant hepatic arterial plus systemic chemotherapy (HAIC + Sys) in patients with early CLM. Methods: A retrospective analysis of patients with early CLM (<12 months of adjuvant chemotherapy for primary tumor) who received either HAIC + Sys, adjuvant systemic chemotherapy alone (Sys), or active surveillance (Surgery alone) following resection of CLM was performed. Recurrence and survival were compared between treatment groups using Kaplan-Meier methods and Cox proportional hazards models. Results: Of 239 patients undergoing resection of early CLM, 79 (33.1%) received HAIC + Sys, 77 (32.2%) received Sys, and 83 (34.7%) had Surgery alone. HAIC + Sys was independently associated with reduced risk of RFS events (adjusted hazard ratio [HRadj]: 0.64, 95%CI:0.44-0.94, p = 0.022) and all cause mortality (HRadj: 0.54, 95%CI:0.36-0.81, p = 0.003) compared to Surgery alone patients. Largest tumor >5 cm (HRadj: 2.03, 95%CI: 1.41-2.93, p < 0.001) and right-sided colon tumors (HRadj: 1.93, 95%CI: 1.29-2.89, p = 0.002) were independently associated with worse OS. Conclusion: Adjuvant HAIC + Sys after resection of early CLM that occur after chemotherapy for node positive primary is associated with improved outcomes.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 50 条
  • [21] Adjuvant chemotherapy for stage III colon cancer in the oldest old
    Abraham, Anasooya
    Habermann, Elizabeth B.
    Rothenberger, David A.
    Kwaan, Mary
    Weinberg, Armin D.
    Parsons, Helen M.
    Gupta, Pankaj
    Al-Refaie, Waddah B.
    CANCER, 2013, 119 (02) : 395 - 403
  • [22] Adjuvant therapy of colorectal cancer From coffee to acetylsalicylic acid to chemotherapy
    Kraeft, A-L
    Reinacher-Schick, A.
    Folprecht, G.
    GASTROENTEROLOGE, 2020, 15 (04): : 290 - 299
  • [23] Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer
    Nakayama, Izuma
    Suenaga, Mitsukuni
    Wakatsuki, Takeru
    Ichimura, Takashi
    Ozaka, Masato
    Takahari, Daisuke
    Shinozaki, Eiji
    Chin, Keisho
    Ueno, Masashi
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (01) : 133 - 139
  • [24] The role of adjuvant chemotherapy in stage II colorectal cancer patients
    Lin, Hung-Hsin
    Chang, Yu-Yao
    Lin, Jen-Kou
    Jiang, Jeng-Kai
    Lin, Chun-Chi
    Lan, Yuan-Tzu
    Yang, Shung-Haur
    Wang, Huann-Sheng
    Chen, Wei-Shone
    Lin, Tzu-Chen
    Chang, Shih-Ching
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2014, 29 (10) : 1237 - 1243
  • [25] Recurrence and cancer-specific death after adjuvant chemotherapy for Stage III colon cancer
    Chapuis, P. H.
    Bokey, E.
    Chan, C.
    Keshava, A.
    Rickard, M. J. F. X.
    Stewart, P.
    Young, C. J.
    Dent, O. F.
    COLORECTAL DISEASE, 2019, 21 (02) : 164 - 173
  • [26] Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer
    Suenaga, Mitsukuni
    Cao, Shu
    Zhang, Wu
    Matsusaka, Satoshi
    Okazaki, Satoshi
    Berger, Martin D.
    Miyamoto, Yuji
    Schirripa, Marta
    Barzi, Afsaneh
    Yamamoto, Noriko
    Yamaguchi, Toshiharu
    Lenz, Heinz-Josef
    PHARMACOGENETICS AND GENOMICS, 2021, 31 (01) : 10 - 16
  • [27] Impact of Anatomic Extent of Nodal Metastasis on Adjuvant Chemotherapy Outcomes in Stage III Colon Cancer
    Woo, In Teak
    Park, Jun Seok
    Kang, Byung Woog
    Park, Soo Yeun
    Kim, Hye Jin
    Choi, Gyu-Seog
    Gwang Kim, Jong
    DISEASES OF THE COLON & RECTUM, 2020, 63 (10) : 1455 - 1465
  • [28] Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
    Khalil, Lana
    Gao, Xingyu
    Switchenko, Jeffrey M.
    Alese, Olatunji B.
    Akce, Mehmet
    Wu, Christina
    Diab, Maria
    El-Rayes, Bassel F.
    Shaib, Walid L.
    ONCOLOGIST, 2022, 27 (09) : 740 - 750
  • [29] Optimizing Adjuvant Therapy after Surgery for Colorectal Cancer Liver Metastases: A Systematic Review
    Georgilis, Emmanouil
    Gavriatopoulou, Maria
    Tsilimigras, Diamantis I.
    Malandrakis, Panagiotis
    Theodosopoulos, Theodosios
    Ntanasis-Stathopoulos, Ioannis
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (06)
  • [30] Differences in prognosis and underuse of adjuvant chemotherapy between elderly and non-elderly patients in stage III colorectal cancer
    Shiraishi, Takuya
    Ogawa, Hiroomi
    Shioi, Ikuma
    Ozawa, Naoya
    Osone, Katsuya
    Okada, Takuhisa
    Sohda, Makoto
    Shirabe, Ken
    Saeki, Hiroshi
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (01): : 91 - 101